Wound healing activity of miroencapsulated of crude ethanolic extract obtained from Arrabidaea chica(Humb. & Bonpl.) Verlot

Author(s)

Michelle Pedroza Jorge

• Document type: Doctoral Thesis
• Press: Campinas, SP.
• Institution: Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas
• Defense date: 2013-09-13

Examining board members

João Ernesto de Carvalho; Hervé Louis Ghislain Rogez; Humberto Moreira Spindola; Luz Mária Sánches Perera; Andrea Aparecida de Aro

• Advisor: João Ernesto de Carvalho

Abstract

Wound healing is a dynamic and complex physiological process that aims restoring function and anatomical continuity of tissues. The species Arrabidea chica (Humb. & Bonpl.) Verlot, found throughout Brazil and part of the national list of medicinal plants of interest to the SUS (Renisus), is popularly used to wound healing. Based on previous pharmacological studies, this thesis aimed to improve the quality and stability of A. chica crude extract (EB) through microencapsulation by atomization process affording microencapsulated crude extract (EBM). Stability study comparing EB and EBM phytochemical and pharmacological aspects showed that the microencapsulation process was able to avoid chemical decomposition of three anthocyanidins used as chemical markers as well as to keep the antiulcer activity. Further mechanism of action studies have demonstrated that the protective gastric effect of EB (dose 125 mg / kg) involves modulation of mucus and gastric acid production, evidenced by mucus dosage and pylorous ligation models in rats. Moreover, antisecretory mechanisms of action of EB could be related to an antagonistic action on gastrin and acetylcholine receptors probably acting on second messengers. In order to evidence angiogenic activity of EB, studies have been conducted on chorioallantoic membrane (CAM) of eggs and dorsum integument of mice showing that EB has pro-angiogenic effects. Furthermore, the wound healing effect of EB and EBM have been evaluated on dermal ulcer model in streptozotocin-induced diabetic rats affording that topical administration of EB or EBM had reduced the ulcerated area in 85 % and 86 %, respectively, in diabetic animals treated during 10 days been comparable to positive control group (allantoin, 85 % of reduction). Finally, safety assessment of EB at dose of 300 mg/kg has been performed using the 28-day repeated dose oral toxicity assay in rodents, presenting no clinical, pathological, biochemical or hematological toxicity signs. The results of this project stabilished some efficacy, safety and reproducibility parameters providing subsidies for the development of a new herbal medicine from Arrabidea chica crude extract for skin and gastric ulcers treatment, whether not derived from diabetes complications (AU)